Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

November 18, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

July 13, 2026July 13, 2026

Why Do We Age? The Biology Of Ageing Explained

1
October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

2
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

3
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

4
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

5
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • INDIA’S CALL FOR PFIZER AGAINST COVID 19

Camouflage: an invisibility cloak?

Food Inhibiting Enzyme That Causes COVID Replication

INDIA’S CALL FOR PFIZER AGAINST COVID 19
  • BiotechToday
  • India

INDIA’S CALL FOR PFIZER AGAINST COVID 19

bioxone December 8, 2020December 8, 2020

SHRESTHA DUTTA, AMITY UNIVERSITY KOLKATA

The authorization for Pfizer’s vaccine candidate came in just 10 months since it initiated developing it, which is the fastest in the history of vaccines.

Pfizer has become the main organization to seek emergency use endorsement of its immunization applicant in India after getting clearance in the UK and Bahrain. Pfizer Inc and BioNTech SE vaccine candidate, BNT162b2, has demonstrated 95 percent viability against Covid during a preparatory clinical trial data examination. It has been approved by the Drugs Controller General of India for emergency use authorization. The advancement is significant since Prime Minister Narendra Modi, during an all-party meet on Friday, referred to specialists to state that India could have the first Covid immunization in weeks and that eight vaccines will be fabricated in India.

An official source reported to a news organization that Pfizer India has presented an application on December 4 to the DCGI looking for emergency use authorization (EUA) for its COVID-19 antibody in India and has sought consent to import the immunization available to be purchased and distributed. It additionally looked for the waiver of clinical preliminaries on the Indian population according to the special arrangements under the New Drugs and Clinical Trials Rules, 2019, to get moment endorsement for emergency use as announced. AIIMS Delhi Director Dr. Randeep Guleria had before said that India was in talks with Pfizer-BioNTech in regards to its COVID-19 antibody candidate. He additionally added that no such correspondence had been started with Moderna for its trial COVID-19 immunization.

Also read: Camouflage: an invisibility cloak?

SOURCE: Pfizer seeks approval for emergency use in India after nod in UK, Bahrain (businesstoday.in)

  • Why Do We Age? The Biology Of Ageing Explained
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged Covid antibodies Covid-19 vaccine Pfizer approval Pfizer approved in uk pfizer biontech Pfizer biontech vaccine Pfizer covid vaccine Pfizer vaccine update

One thought on “INDIA’S CALL FOR PFIZER AGAINST COVID 19”

  1. Pingback: Food Inhibiting Enzyme That Causes COVID Replication - BioXone

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

Food Inhibiting Enzyme That Causes COVID Replication

bioxone December 8, 2020

Thota Kanishka Rao, Amity University Kolkata Chemical compounds in some food or beverages, like green tea, muscadine grapes, and dark chocolate have been known to bind to and block the function of a protease, in the SARS-CoV-2 virus, according to researchers. Proteases are essential to the health and viability of cells and viruses. On the […]

Food

Related Post

  • BiotechToday
  • World

Sputnik V- single dose usage against COVID-19

BioTech Today July 16, 2021July 15, 2021

Kanikah Mehndiratta, MSc, University of Glasgow Amongst so many vaccine options recently developed in different parts of the world, Sputnik V has proven to be a great candidate due to a lot of factors. Firstly, is its high efficacy of about 92% against the coronavirus disease caused by the SARS-CoV2 viral strains. Also known as […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Building a chemical blueprint for human blood

bioxone November 16, 2020November 16, 2020

Sagnik Nag, Amity University Kolkata  Our blood serves as an imperative circulatory fluid transporting many chemical substances and respiratory gases throughout the body. There are certain molecules present in the blood which serve as markers providing indications towards the state of our health. Molecules such as hormones and drugs directly or indirectly affect the health […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Vaccine for Covid positive HIV patients

BioTech Today June 21, 2021June 20, 2021

Agrima Bhatt, Rajasthan University SARS-CoV-2 vaccination data has proven to lower the morbidity and mortality associated with COVID-19. However, this data severely lacks research among people suffering from immunodeficiency disorders, such as AIDS. In events of such opportunistic infections, where the human body is unable to produce the required immune response, the person is said […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

Why Do We Age? The Biology Of Ageing Explained

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy